loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Dr Agarwals Health Care Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Dr. Agarwals Health Care Ltd. 05 Nov 2026 18:44 PM

Q2FY27 Quarterly Result Announced for Dr. Agarwals Health Care Ltd.

Healthcare Facilities company Dr. Agarwals Health Care announced Q2FY27 results

Standalone Financial Highlights:

  • Revenue from operations for Q2FY27 was Rs 564.56 crore, representing a QoQ growth of 7.41% over Rs 525.59 crore in Q1FY27 and a YoY expansion of 32.31% over Rs 426.70 crore in Q2FY26. For H1FY27, revenue stood at Rs 1,090.15 crore, reflecting a YoY growth of 28.96% compared to Rs 845.34 crore in H1FY26.
  • Total income for Q2FY27 was Rs 572.95 crore, indicating an increase of 7.95% sequentially from Rs 530.76 crore in Q1FY27 and a YoY improvement of 32.37% against Rs 432.84 crore in Q2FY26. For H1FY27, total income reached Rs 1,103.71 crore, displaying a YoY rise of 27.58% over Rs 865.13 crore in H1FY26.
  • Profit Before Tax (PBT) for Q2FY27 stood at Rs 59.27 crore, presenting a QoQ increase of 10.87% compared to Rs 53.46 crore in Q1FY27 and a YoY expansion of 73.81% relative to Rs 34.10 crore in Q2FY26. For H1FY27, standalone PBT arrived at Rs 112.73 crore, showing a YoY rise of 54.68% over Rs 72.88 crore in H1FY26.
  • Profit After Tax (PAT) for Q2FY27 concluded at Rs 43.52 crore, up 8.66% sequentially from Rs 40.05 crore in Q1FY27 and up 90.71% YoY relative to Rs 22.82 crore in Q2FY26. For H1FY27, standalone PAT totalised Rs 83.57 crore, yielding a YoY expansion of 66.51% over Rs 50.19 crore in H1FY26.
  • Earnings Per Share (EPS) (Basic) for Q2FY27 printed at Rs 1.31, increasing sequentially by 8.26% over Rs 1.21 in Q1FY27 and increasing by 87.14% YoY over Rs 0.70 in Q2FY26. For H1FY27, basic EPS stood at Rs 2.52, tracking a YoY rise of 65.79% against Rs 1.52 in H1FY26.

Consolidated Financial Highlights:

  • Revenue from operations for Q2FY27 came in at Rs 655.46 crore, registering a QoQ expansion of 6.75% relative to Rs 614.02 crore in Q1FY27 and a YoY expansion of 31.44% against Rs 498.69 crore in Q2FY26. For H1FY27, it totalised Rs 1,269.48 crore, marking a YoY growth of 28.74% from Rs 986.11 crore in H1FY26.
  • Total income for Q2FY27 posted at Rs 665.21 crore, marking a QoQ growth of 7.22% compared to Rs 620.43 crore in Q1FY27 and a YoY growth of 31.30% over Rs 506.62 crore in Q2FY26. For H1FY27, total consolidated income closed at Rs 1,285.64 crore, moving up 27.65% YoY relative to Rs 1,007.13 crore in H1FY26.
  • Profit Before Tax (PBT) for Q2FY27 arrived at Rs 79.89 crore, documenting a sequential QoQ rise of 6.32% against Rs 75.14 crore in Q1FY27 and a YoY increase of 48.88% relative to Rs 53.66 crore in Q2FY26. For H1FY27, consolidated PBT reached Rs 155.03 crore, reflecting a YoY climb of 44.54% over Rs 107.26 crore in H1FY26.
  • Profit After Tax (PAT) for Q2FY27 totalised Rs 56.85 crore, indicating a sequential QoQ optimization of 3.33% over Rs 55.02 crore in Q1FY27 and a YoY growth of 55.79% against Rs 36.49 crore in Q2FY26. For H1FY27, consolidated PAT reached Rs 111.87 crore, representing a YoY increase of 50.06% compared to Rs 74.55 crore in H1FY26.
  • Earnings Per Share (EPS) (Basic) for Q2FY27 printed at Rs 1.65, showing a step up of 6.45% QoQ from Rs 1.55 in Q1FY27 and a YoY jump of 54.21% compared to Rs 1.07 in Q2FY26. For H1FY27, basic EPS totalised Rs 3.20, defining a YoY growth of 51.66% against Rs 2.11 in H1FY26.

Adil Agarwal, CEO, Dr. Agarwal’s Health Care, said: “The H1FY27 has been a defining period for us, marked by strong growth across our key metrics. Revenue from Operations grew 28.7% YoY to Rs 1,269 crore, and Q2 was our highest-ever quarter at Rs 655 crore. Our mature hospitals continue to lead this growth, with same-store sales growth of 17.7%. EBITDA rose 27.0% to Rs 362 crore despite the investment in new centres, and Profit after Tax grew 50.1% to Rs 112 crore.

We added 39 facilities during the half year, taking our network to 324 facilities across India and Africa. In the first half alone, we added more surgical facilities than in all of FY26. We served over 18.4 lakh patients, up 28.5%, and performed c.1.87 lakh surgeries, up 18.8%, supported by a team of 1,100 doctors. Patients are also increasingly choosing advanced care, with high-end surgeries contributing ~30% of cataract volumes.

Beyond these numbers, we continue to push the frontier of eye care. I am pleased to share that we have now opened the world’s first dedicated Pinhole Pupilloplasty (PPP) centre at our Chennai flagship facility. It is a proud milestone for Dr. Agarwal’s and reflects our commitment to clinical innovation. We now intend to take PPP across our network and globally, so that many more patients can benefit from it.”

Result PDF

Healthcare Facilities company Dr. Agarwals Health Care announced Q1FY27 results

Consolidated Financial Highlights:

  • Revenue from Operations: The company reported revenue of Rs 614.02 crore in Q1FY27, a growth of 26.0% compared to Rs 487.42 crore in Q1FY26. On a QoQ basis, revenue grew by 8.85% from Rs 564.11 crore in Q4FY26.
  • Total Income: Total income for Q1FY27 stood at Rs 620.43 crore, reflecting a YoY growth of 23.9% from Rs 500.81 crore in Q1FY26 and a QoQ increase of 7.58% from Rs 576.69 crore in Q4FY26.
  • EBITDA: EBITDA grew by 25.2% YoY to Rs 176.82 crore in Q1FY27 from Rs 141.25 crore in Q1FY26. QoQ EBITDA increased by 1.59% from Rs 174.05 crore in Q4FY26.
  • EBITDA Margin: The EBITDA margin for Q1FY27 was 28.5% compared to 28.2% in Q1FY26.
  • Profit After Tax (PAT): PAT for Q1FY27 stood at Rs 55.02 crore, an increase of 44.6% YoY from Rs 38.06 crore in Q1FY26. On a QoQ basis, PAT grew by 10.13% from Rs 49.96 crore in Q4FY26.
  • PAT Margin: The PAT margin for the quarter was 8.9% compared to 7.6% in Q1FY26.

Standalone Financial Highlights:

  • Revenue from Operations: Standalone revenue was Rs 382.62 crore in Q1FY27, up 26.8% YoY from Rs 301.72 crore in Q1FY26 and up 9.99% QoQ from Rs 347.86 crore in Q4FY26.
  • Total Income: Standalone total income stood at Rs 386.04 crore in Q1FY27, a growth of 22.65% YoY from Rs 314.75 crore in Q1FY26 and 9.03% QoQ from Rs 354.07 crore in Q4FY26.
  • EBITDA: Standalone EBITDA was Rs 98.99 crore in Q1FY27, a growth of 24.0% YoY from Rs 79.83 crore in Q1FY26 and 0.93% QoQ from Rs 98.08 crore in Q4FY26.
  • Profit After Tax (PAT): Standalone PAT for Q1FY27 was Rs 16.67 crore, representing a 64.89% YoY growth from Rs 10.11 crore in Q1FY26 and a 57.26% QoQ increase from Rs 10.60 crore in Q4FY26.

Business Highlights:

  • Network Expansion: As of June 30, 2026, the company's network reached 304 facilities. During the quarter, 18 new facilities were added, consisting of 1 Tertiary, 15 Secondary, and 2 Primary facilities.
  • Surgical Performance: The company performed 91,082 surgeries in Q1FY27, marking a growth of 15.5% YoY.
  • Greenfield Projects: The company commissioned 16 new surgical facilities in Q1FY27, which is the highest ever in a single quarter for the firm.
  • Segment-wise Performance (Consolidated):
    • India Operations: Revenue from India stood at Rs 552 crore, a growth of 25.3% YoY.
    • Mature Facilities: Revenue from mature facilities was Rs 485 crore, growing at 37.1% YoY.
    • Revenue Mix: Sale of Services contributed 77.7%, and Sale of Products contributed 22.3% to revenue from operations.
  • Corporate Developments:
    • Nigeria Expansion: The company proposed the incorporation of a wholly-owned subsidiary in Nigeria, 'Orbit Health Care Services (Nigeria) Ltd', to engage in comprehensive eye care services.
    • Audit Appointments: M/s. S.R. Batliboi & Associates LLP were appointed as Statutory Auditors until the conclusion of the 20th AGM. M/s. KPMG Assurance and Consulting Services LLP were appointed as Internal Auditors for the financial year 2026-27.
    • IPO Proceeds: Out of the fresh issue proceeds of Rs 300 crore, the company has utilized Rs 282.31 crore up to June 30, 2026. The unutilized amount of Rs 17.69 crore is intended for general corporate purposes.

Adil Agarwal, CEO, Dr. Agarwal’s Health Care, said: “This has been an exceptional quarter for us on multiple fronts. We delivered our highest ever sequential quarter-on-quarter revenue growth, underscoring the strong momentum across our business. We also set a new record with the launch of 16 greenfield surgical facilities in a single quarter — the highest ever in our history. Revenue from operations for the quarter stood at Rs 614 crore, a growth of 26.0% over the same period last year, driven by healthy growth across all of our regions. Our EBITDA rose by 25.2% to Rs 177 crore, underscoring our focus on operational efficiency and cost discipline despite rising greenfield losses driven by 23 surgical facilities launched in the last six months. Profit after tax rose to Rs 55 crore, up 44.6% year-on-year.

Operationally, our network grew to 304 eye care facilities as of June 30, 2026, with 18 new additions during the quarter. We served over 8.8 lakh patients and performed c.91,000 surgeries, supported by our team of 1,050 doctors. Q1FY27 witnessed a record addition of 16 surgical facilities, delivering nearly half of FY26's total surgical facility additions in a single quarter. Our greenfield execution engine is firing, and with a strong pipeline already in place, we remain confident of delivering on the full-year plan.”

Result PDF

Healthcare Facilities company Dr. Agarwals Health Care announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Total Income:
    • For Q4FY26, total income stood at Rs 577 crore, representing a YoY growth of 21.2% from Rs 476 crore in Q4FY25 and a QoQ growth of 6.77% from Rs 540.40 crore in Q3FY26.
    • For the full year FY26, total income reached Rs 2,125 crore, up 20.9% YoY from Rs 1,757 crore in FY25.
  • Revenue from Operations:
    • In Q4FY26, revenue was Rs 564.11 crore, reflecting a YoY increase of 22.57% compared to Rs 460.22 crore in Q4FY25 and a QoQ increase of 6.46% from Rs 529.86 crore in Q3FY26.
    • Annual revenue for FY26 grew by 21.57% YoY to Rs 2,080.08 crore from Rs 1,711 crore in FY25.
  • EBITDA and Margins:
    • EBITDA for Q4FY26 was Rs 174 crore, showing a YoY growth of 18.9% from Rs 146 crore and a QoQ growth of 12.55% from Rs 154.64 crore. EBITDA margins for the quarter stood at 30.2%.
    • For FY26, EBITDA reached Rs 614 crore, growing by 22.2% YoY from Rs 502 crore in FY25, with an annual margin of 28.9%.
  • Profit After Tax (PAT):
    • For Q4FY26, PAT was Rs 50 crore, up 17.4% YoY from Rs 43 crore and up 14.51% QoQ from Rs 43.63 crore.
    • For the full year FY26, PAT soared by 52.4% YoY to Rs 168 crore compared to Rs 110 crore in FY25.
  • Earnings Per Share (EPS):
    • Annual Basic EPS for FY26 stood at Rs 4.21, compared to Rs 2.80 in FY25.

Standalone Financial Highlights:

  • Total Income:
    • Q4FY26 total income was Rs 354.07 crore, compared to Rs 307.95 crore in Q4FY25 and Rs 341.95 crore in Q3FY26.
    • Full year FY26 total income stood at Rs 1,326.55 crore, up from Rs 1,097.70 crore in FY25.
  • Revenue from Operations:
    • Revenue for Q4FY26 was Rs 347.86 crore, a growth of 23.78% YoY from Rs 281.02 crore and 3.89% QoQ from Rs 334.84 crore.
    • Annual revenue for FY26 reached Rs 1,293.39 crore, up 23.90% YoY from Rs 1,043.89 crore in FY25.
  • Profit After Tax (PAT):
    • Q4FY26 PAT was Rs 10.60 crore, a decrease compared to Rs 26.51 crore in Q4FY25 and Rs 14.06 crore in Q3FY26.
    • Full year FY26 PAT stood at Rs 39.45 crore, representing a growth of 79.89% YoY from Rs 21.93 crore in FY25.

Business Highlights:

  • Network Expansion: As of March 31, 2026, the company operates a network of 288 facilities across 10 countries. During FY26, the company commissioned 57 new facilities (one every single week), entering 26 new cities. The Q4FY26 alone saw the addition of 19 new centers.
  • Segment Performance: The Group operates in a single reportable segment, namely "Eye Care related sales and services."
  • Surgical Volume: The company performed 84,962 surgeries in Q4FY26 ( 23.6% YoY) and a total of 323,245 surgeries in FY26 ( 14.5% YoY).
  • Revenue Contribution: For the full year FY26, sale of services contributed 78.4% of revenue, while sale of products contributed 21.6%. Mature facilities revenue grew by 35.3% YoY to reach Rs 1,632 crore.
  • IPO Proceeds Reallocation: The Board approved the reallocation of the unspent portion of "Issue Related Expenses" amounting to Rs 14.884 crore to "General Corporate Purposes and Unidentified Inorganic Acquisitions." Total unutilized IPO proceeds as of March 31, 2026, stood at Rs 23.141 crore.
  • Strategic Moves:
    • The company acquired the remaining stake in Aditya Jyot Eye Hospital Private Limited, making it a wholly-owned subsidiary.
    • A proposed scheme of amalgamation with its subsidiary, Dr. Agarwal's Eye Hospital Limited (AEHL), was approved by the Board and is subject to further regulatory approvals.
    • The company successfully entered the Delhi NCR region through organic growth, establishing six operational facilities within twelve months.

Adil Agarwal, CEO, Dr. Agarwal’s Health Care, said: "FY2026 has been a landmark year for Dr. Agarwal's Health Care on every dimension. For the first time in our history, we crossed Rs 2,000 crore in revenues from operations — a milestone that reflects the trust of over 30 lakh patients and the dedication of every doctor and team member across our network. Revenue from operations grew 21.6%, EBITDA expanded 22.2% to Rs 614 crore with margins at 28.9%, and profit after tax grew 52.4% to Rs 168 crore.

On the network front, FY2026 saw us commission 57 new facilities — one every single week — entering 26 new cities and taking our total network to 288 facilities across 10 countries. Of the 57 additions, 30 were surgical centres, further strengthening our clinical capacity. Our entry into Delhi NCR, pursued entirely through organic growth, has also been a particular highlight with six facilities now operational across the region in under twelve months.

A year ago, we set out with clear targets. Today, we close the year having delivered on each one of them. We enter FY2027 with strong momentum, conviction, and a clear plan to expand faster, deliver ever higher standards of clinical excellence, and serve more patients than ever before.”

Result PDF

Healthcare Facilities company Dr. Agarwals Health Care announced Q3FY26 results

  • As of December 31, 2025, our network stands at 272 facilities, with 14 new centers added during the quarter comprising of 9 secondary and 5 primary facilities.
  • Performed 81,002 surgeries in Q3FY26, growth of 11.2% YoY.
  • Total Income of Rs 540 crore; growth of 21.9% YoY.
  • Revenue from Operations of Rs 530 crore; growth of 23.0% YoY.
    • Revenue from Operations - India of Rs 480 crore, growth of 23.1% YoY.
    • Revenue from Mature Facilities of Rs 405 crore, growth of 37.8% YoY.
  • Sale of Services contributed 78.8% and Sale of Products contributed 21.2% to revenue from operations.
  • EBITDA of Rs 155 crore, growth of 21.3% YoY with EBITDA margins of 28.6%.
  • Profit after Tax of Rs 44 crore, growth of 54.5% YoY with profit after tax margins of 8.1%.

Adil Agarwal, CEO, Dr. Agarwal’s Health Care, said: “The Company delivered a strong performance in Q3FY26, marked by robust growth across revenues and profitability, reflecting sustained execution momentum. For the Q3FY26, Revenue from Operations grew by 23.0% YoY to Rs 530 crore, driven by healthy patient volumes, strong traction across mature centres, and improving contribution from newer facilities. EBITDA increased by 21.3% YoY to Rs 155 crore, underscoring the resilience of the operating model and disciplined cost management.

On the operational front, our network expanded to 272 eye care facilities as of December 31, 2025 with 38 additions during the nine months period ending December, 2025. We served over 22 lakh patients and performed over 238,000 surgeries, supported by our team of 900 doctors.

The Company remains focused on accelerating organic growth through aggressive greenfield expansion, deepening its presence in existing markets while selectively entering newer geographies. Leveraging its brand strength and scalable platform, Dr. Agarwal’s Healthcare continues to drive sustainable growth while maintaining high standards of patient safety and clinical quality. The Company remains confident of meeting its annual guidance, supported by resilient demand and strong momentum in its expansion plans.”

Result PDF

Healthcare Facilities company Dr. Agarwals Health Care announced Q2FY26 results

  • As of September 30, 2025, our network stands at 258 facilities, with 11 new centers added during the quarter comprising of 6 secondary and 5 primary facilities - Performed 78,399 surgeries in Q2FY26, growth of 13.3% YoY.
  • Total Income of Rs 507 crore; growth of 18.2% YoY.
  • Revenue from Operations of Rs 499 crore; growth of 19.7% YoY.
    • Revenue from Operations. India of Rs 445 crore, growth of 19.8% YoY.
    • Revenue from Mature Facilities of Rs 371 crore, growth of 12.7% YoY.
  • Sale of Services contributed 78.1% and Sale of Products contributed 21.7% to revenue from operations.
  • EBITDA of Rs 144 crore, growth of 21.2% YoY with EBITDA margins of 28.4%.
  • Profit after Tax of Rs 36 crore, growth of 71.0% YoY with profit after tax margins of 7.2%.

Adil Agarwal, CEO, Dr. Agarwal’s Health Care, said: “The company delivered a steady performance in H1FY26 crossing the Rs 1,000 crore Total Income milestone for the first time — marking a significant achievement in its growth journey. EBITDA for H1FY26 grew by 24.9% YoY to Rs 285 crore, and profit after tax rose by 88.4% to Rs 75 crore, reflecting improved operating efficiencies, disciplined cost management, and stronger margins. While topline growth moderated compared to the previous quarter due to festivities and heavy rainfall, margins strengthened, demonstrating continued focus on profitability and operational excellence.

On the operational front, our network expanded to 258 eye care facilities as of September 30, 2025 with 24 additions during the first half. We served over 14 lakh patients and performed over 157,000 surgeries, supported by our team of 880 doctors. Our recent entry into the Delhi market has seen encouraging traction, and we plan to further accelerate our expansion across North India. We remain confident of meeting our annual guidance, driven by resilient demand and the momentum in our expansion plans. As the second half of the year typically delivers stronger performance, we expect the momentum to further build through FY26.”

Result PDF

Healthcare Facilities company Dr. Agarwals Health Care announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue from Operations of Rs 460 crore, growth of 31.9% YoY
    • Revenue from Operations — India of Rs 413 crore, growth of 34.2% YoY
    • Revenue from Mature Facilities of Rs 332 crore, growth of 28.9% YoY
  • EBITDA of Rs 146 crore, growth of 15.1% YoY with EBITDA margin of 30.8%
  • Profit after Tax of Rs 43 crore, growth of 3.0% YoY with PAT margin of 8.9%
  • 236 Facilities as of March 31, 2025
    • 17 Facilities have been added in Q4FY25

FY25 Financial Highlights:

  • Revenue from Operations of Rs 1,711 crore; growth of 28.4% YoY
    • Revenue from Operations — India of Rs 1,538 crore, growth of 32.4% YoY
    • Revenue from Mature Facilities of Rs 1,206 crore, growth of 18.5% YoY
  • Sale of Services contributed 79.0% and Sale of Products® contributed 21.0% to revenue from operations
  • EBITDA of Rs 502 crore, growth of 23.6% YoY with EBITDA margins of 28.6%
  • Profit after Tax of Rs 110 crore, growth of 16.1% YoY with profit after tax margins of 6.3%
  • 59 Facilities were added in 12M FY2025
    • Of these 52 new Facilities have been set up and 7 Facilities have been acquired
  • Performed 282,326 surgeries in 12M FY2025, growth of 28.0% YoY

Commenting on Q4FY25 and Twelve Months ended March 31, 2025 results, Adil Agarwal, CEO, Dr. Agarwal’s Health Care, said: “We are pleased to announce our first annual results post-listing, recording a strong 31.9% revenue growth that reflects the sustained momentum in our operations. In India, we expanded our network from 165 to 218 centres, reinforcing our commitment to accessible, high-quality eye care. We remain committed to growth and see significant untapped potential in the Indian eye care market. Organized eye care chains like ours currently serve just 13—15% of the market, while the remaining 85-87% is fragmented across standalone hospitals, clinics, community- and trustrun institutions, and government facilities. This fragmentation presents a compelling opportunity for us to consolidate and scale. We aim to capitalize on this potential by increasing patient volumes per center, strengthening referral networks, executing targeted marketing initiatives, and maintaining an unwavering focus on patient satisfaction. With these growth drivers in place, we are committed to accelerating our financial performance in the years ahead and doing so by scaling smartly, growing responsibly, and leading purposefully.”

Result PDF

Healthcare Facilities company Dr. Agarwals Health Care announced Q3FY25 results

  • Revenue: Increased by 29.5% YoY, reaching Rs 430.7 crore compared to Rs 332.7 crore in Q3FY24.
  • Other Income stood at Rs 12.7 crore in Q3FY25.
  • EBITDA stood at Rs 118.9 crore in Q3FY25, a 26.3% increase from Rs 101.0 crore in Q3FY24.
  • EBITDA margin was at 27.8% in Q3FY25, compared to 27.7% in Q3FY24.
  • PBT stood at Rs 41.0 crore for Q3FY25, growing by 13.8% compared to Rs 36.0 crore in Q3FY24.
  • PAT increased by 25.0%, reaching Rs 28.2 crore in Q3FY25 from Rs 22.6 crore in Q3FY24.

Amar Agarwal, Chairman, said: " February 4, 2025, marked a remarkable achievement in our journey, with the successful listing of our company a testament to the dedication of our team and the trust of our patients.This milestone reinforces our commitment to delivering world-class eye care and advancing the field of vision health.

We are also committed to driving research and embracing the latest technological advancements to offer the best possible treatments for all our patients. Furthermore, we aim to empower communities by increasing awareness of eye health, ensuring that eye care becomes accessible to everyone, no matter where they live.

This is just the beginning, and together, we will continue to shine a brighter light on the future of eye care."

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app